LUNG CANCER

Scope & Guideline

Empowering Research, Enhancing Lives

Introduction

Welcome to your portal for understanding LUNG CANCER, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0169-5002
PublisherELSEVIER IRELAND LTD
Support Open AccessNo
CountryIreland
TypeJournal
Convergefrom 1985 to 2024
AbbreviationLUNG CANCER / Lung Cancer
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE 00000, IRELAND

Aims and Scopes

The journal "LUNG CANCER" focuses on advancing the understanding, diagnosis, and treatment of lung cancer through a multidisciplinary approach. It aims to publish high-quality research that contributes to clinical practices and enhances patient outcomes.
  1. Focus on Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC):
    The journal predominantly explores both NSCLC and SCLC, covering various aspects including diagnosis, treatment modalities, and patient outcomes.
  2. Emphasis on Immunotherapy and Targeted Therapy:
    Significant research is dedicated to immunotherapeutic approaches, particularly immune checkpoint inhibitors, and targeted therapies focusing on specific mutations like EGFR, MET, and ALK.
  3. Clinical Trials and Real-World Studies:
    The journal publishes findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and patient management strategies.
  4. Molecular and Genomic Characterization:
    Research on the molecular and genomic landscape of lung cancer, including genetic mutations and their implications for treatment, is a core area of focus.
  5. Patient-Centered Outcomes and Quality of Life:
    The journal also emphasizes studies that assess patient-reported outcomes, preferences, and quality of life, recognizing the importance of patient-centered approaches in lung cancer care.
The journal "LUNG CANCER" has seen a rise in certain themes in recent years, reflecting the evolving landscape of lung cancer research and treatment.
  1. Integration of AI and Machine Learning:
    There is a growing trend towards utilizing artificial intelligence and machine learning for predictive modeling in lung cancer, enhancing diagnostic accuracy and treatment planning.
  2. Focus on Combination Therapies:
    Research increasingly examines the efficacy of combination therapies that integrate immunotherapy with chemotherapy or targeted therapies, aiming for synergistic effects in treatment outcomes.
  3. Personalized Medicine and Biomarker Research:
    A significant emphasis is placed on personalized medicine, particularly studies focusing on biomarkers that guide treatment decisions and predict patient responses to therapies.
  4. Longitudinal and Follow-Up Studies:
    There is an emerging trend in conducting longitudinal studies to evaluate long-term outcomes and the impact of treatment strategies over time, enhancing understanding of survivorship.
  5. Management of Comorbidities in Lung Cancer Patients:
    Research is increasingly addressing the management of comorbidities in lung cancer patients, recognizing the complex interplay between cancer treatment and overall health.

Declining or Waning

While "LUNG CANCER" continues to evolve, certain themes have become less prominent in recent publications, indicating a potential shift in research focus.
  1. Traditional Chemotherapy Protocols:
    Research related to standard chemotherapy protocols appears to be declining as newer targeted therapies and immunotherapies take precedence in treatment discussions.
  2. Surgical Techniques Without Adjuvant Therapy:
    There is a noticeable reduction in studies focusing solely on traditional surgical techniques without the integration of adjuvant therapies, reflecting a shift towards more comprehensive treatment approaches.
  3. Epidemiological Studies on Smoking:
    While smoking remains a significant risk factor for lung cancer, studies specifically focusing on smoking epidemiology are less frequent, as the focus shifts to molecular and genetic factors.
  4. Histopathological Classification Alone:
    The reliance on histopathological classifications without molecular profiling is waning, as there is an increased emphasis on molecular characterization and personalized medicine.

Similar Journals

Kidney Cancer

Transforming research into accessible solutions for kidney cancer.
Publisher: IOS PRESSISSN: 2468-4562Frequency: 2 issues/year

Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.

Molecular Therapy Oncolytics

Exploring the Frontiers of Molecular Medicine in Oncology
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

JOURNAL OF CLINICAL ONCOLOGY

Leading the charge in oncological excellence and discovery.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0732-183XFrequency: 36 issues/year

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

Respiratory Medicine and Research

Transforming respiratory medicine through research.
Publisher: ELSEVIERISSN: Frequency: 2 issues/year

Respiratory Medicine and Research, published by Elsevier, is a pivotal journal in the field of Pulmonary and Respiratory Medicine, dedicated to advancing the understanding and treatment of respiratory diseases. Since its inception in 2019, the journal has provided a platform for high-quality research, contributing significantly to the scientific community's knowledge base, as reflected in its impressive Q2 categorization in 2023. With a Scopus rank of #94 out of 155, placing it in the 39th percentile, this journal is essential for researchers, professionals, and students seeking the latest advancements in respiratory medicine. Although currently categorized as a non-open access publication, it remains accessible to those affiliated with institutions with subscriptions. Published in France, the journal aims to foster collaboration and innovation by highlighting original research, clinical studies, and comprehensive reviews that address pressing issues in respiratory health.

Zeitschrift fur Pneumologie

Bridging Research and Practice in Respiratory Medicine
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Oncology in Clinical Practice

Fostering Collaboration Between Clinicians and Researchers
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

Clinical Lung Cancer

Exploring breakthroughs in lung cancer therapy and research.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Turk Onkoloji Dergisi-Turkish Journal of Oncology

Fostering impactful discoveries in the realm of oncology.
Publisher: KARE PUBLISSN: 1300-7467Frequency: 4 issues/year

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

Cancer Research and Treatment

Innovating solutions for a cancer-free tomorrow.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Cancer Reports

Transforming discoveries into global health solutions.
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.